Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients

Bone Marrow Transplantation

Volumn 37, Issue 7, 2006, Pages 693-698

  van der Heiden, P L J ^a   Kalpoe, J S ^a   Barge, R M ^a   Willemze, R ^a   Kroes, A C M ^a   Schippers, E F ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Allogeneic stem cell transplantation; CMV DNA load; Cytomegalovirus; Ganciclovir; Pre emptive treatment; Valganciclovir

Indexed keywords

ALEMTUZUMAB; ANTIVIRUS AGENT; BUSULFAN; CAMPATH 1G; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; GANCICLOVIR; THYMOCYTE ANTIBODY; VALGANCICLOVIR; VIRUS DNA;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLOOD LEVEL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; GRAFT RECIPIENT; HEMATOLOGIC MALIGNANCY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MONITORING; NONHUMAN; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT; VIRUS LOAD;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; DNA, VIRAL; DRUG TOXICITY; FEMALE; GANCICLOVIR; HUMANS; INJECTIONS, INTRAVENOUS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; VIRAL LOAD;

EID: 33645239275     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705311     Document Type: Article

References (22)

1. Razonable RR. Epidemiology of cytomegalovirus disease in solid organ and hematopoietic stem cell transplant recipients. Am J Health Syst Pharm 2005; 62 (8 Suppl 1): S7-S13.
2. Boeckh M, Nichols WG. The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy. Blood 2004; 103: 2003-2008.
3. Gandhi MK, Khanna R. Human cytomegalovirus: Clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004; 4: 725-738.
4. Goodrich JM, Bowden RA, Fisher L, Keller C, Schoch G, Meyers JD. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993; 118: 173-178.
5. Ljungman P. Beta-herpesvirus challenges in the transplant recipient. J Infect Dis 2002; 186 (Suppl 1): S99-S109.
6. Crumpacker CS. Ganciclovir. N Engl J Med 1996; 335: 721-729.
7. Emery VC. Prophylaxis for CMV should not now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 83-86.
8. Hart GD, Paya CV. Prophylaxis for CMV should now replace pre-emptive therapy in solid organ transplantation. Rev Med Virol 2001; 11: 73-81.
9. Brown F, Banken L, Saywell K, Arum I. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet 1999; 37: 167-176.
10. Pescovitz MD, Rabkin J, Merion RM, Paya CV, Pirsch J, Freeman RB et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 2811-2815.
11. Jung D, Dorr A. Single-dose pharmacokinetics of valganciclovir in HIV- and CMV-seropositive subjects. J Clin Pharmacol 1999; 39: 800-804.
12. Devyatko E, Zuckermann A, Ruzicka M, Bohdjalian A, Wieselthaler G, Rodler S et al. Pre-emptive treatment with oral valganciclovir in management of CMV infection after cardiac transplantation. J Heart Lung Transplant 2004; 23: 1277-1282.
13. Kalpoe JS, Schippers EF, Eling Y, Sijpkens YW, de Fijter JW, Kroes AC. Similar reduction of cytomegalovirus DNA load by oral valganciclovir and intravenous ganciclovir on pre-emptive therapy after renal and renal-pancreas transplantation. Antivir Ther 2005; 10: 119-123.
14. Singh N, Wannstedt C, Keyes L, Gayowski T, Wagener MM, Cacciarelli TV. Efficacy of valganciclovir administered as preemptive therapy for cytomegalovirus disease in liver transplant recipients: Impact on viral load and late-onset cytomegalovirus disease. Transplantation 2005; 79: 85-90.
15. Barge RM, Osanto S, Marijt WA, Starrenburg CW, Fibbe WE, Nortier JW et al. Minimal GVHD following in-vitro T cell-depleted allogeneic stem cell transplantation with reduced-intensity conditioning allowing subsequent infusions of donor lymphocytes in patients with hematological malignancies and solid tumors. Exp Hematol 2003; 31: 865-872.
16. Barge RM, Brouwer RE, Beersma MF, Starrenburg CW, Zwinderman AH, Hale G et al. Comparison of allogeneic T cell-depleted peripheral blood stem cell and bone marrow transplantation: Effect of stem cell source on short- and long-term outcome. Bone Marrow Transplant 2001; 27: 1053-1058.
17. Glucksberg H, Storb R, Fefer A, Buckner CD, Neiman PE, Clift RA et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
18. Shulman HM, Sullivan KM, Weiden PL, McDonald GB, Striker GE, Sale GE et al. Chronic graft-versus-host syndrome in man. A long-term clinicopathologic study of 20 Seattle patients. Am J Med 1980; 69: 204-217.
19. Kalpoe JS, Kroes AC, de Jong MD, Schinkel J, de Brouwer CS, Beersma MF et al. Validation of clinical application of cytomegalovirus plasma DNA load measurement and definition of treatment criteria by analysis of correlation to antigen detection. J Clin Microbiol 2004; 42: 1498-1504.
20. Paya C, Humar A, Dominguez E, Washburn K, Blumberg E, Alexander B et al. Efficacy and safety of valganciclovir vs oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611-620.
21. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34: 1094-1097.
22. Mattes FM, Hainsworth EG, Geretti AM, Nebbia G, Prentice G, Potter M et al. A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients. J Infect Dis 2004; 189: 1355-1361.